RAIN ENHANCEMENT TECHNO-CL A (RAIN) Stock News
NASDAQ:RAIN - Nasdaq - US75080J1034 - Common Stock - Currency: USD
RAIN Latest News, Press Relases and Analysis
Rain Enhancement Technologies Holdco, Inc. Announces Management Updates and Appointment of Randy Seidl as Chief Executive Officer
Pathos AI Completes Acquisition of Rain Oncology
Shareholder Alert: Ademi LLP investigates whether Rain Oncology Inc. has obtained a Fair Price in its transaction with Pathos
/PRNewswire/ -- Ademi LLP is investigating Rain (NASDAQ: RAIN) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Rain Oncology Goes Private Just Two Years After $120M NASDAQ Debut
Rain Oncology Inc (NASDAQ: RAIN) has agreed to be acquired by Pathos AI Inc.
Mentions: JNJ
RAIN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Rain Oncology Inc. Is Fair to Shareholders
Rain Oncology to be acquired by Pathos AI for $1.16 in cash per share (NASDAQ:RAIN)
Rain Oncology (RAIN) has agreed to be acquired by Pathos AI for $1.16, per share in cash and a possibility of cash payments through a value right. Based in Newark, California the oncolog..
Rain Oncology Enters into Agreement to be Acquired by Pathos AI for $1.16 in Cash per Share Plus Contingent Value Rights
NEWARK, Calif., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (Nasdaq: RAIN) (“Rain”), today announced it has entered into a definitive merger...
Rain Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
NEWARK, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN) (Rain) today reported financial results for the third quarter ended...
Rain Oncology Confirms Receipt of Unsolicited Proposal from Concentra Biosciences
NEWARK, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Rain Oncology, Inc. (NasdaqGS: RAIN) (“Rain”) confirmed that it has received an unsolicited proposal...
Rain Oncology gets $1.25/share takeover offer from Tang Capital (NASDAQ:RAIN)
Rain Oncology (RAIN) has received an acquisition proposal from Concentra Biosciences, an affiliate of Tang Capital Partners, for $1.25/share in cash. Read more here.
ROSEN, A TOP RANKED LAW FIRM, Encourages Rain Oncology Inc. Investors to Secure Counsel Before Important September 12 Deadline in Securities Class Action - RAIN
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20,...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Rain Oncology Inc. (RAIN)
SHAREHOLDER ALERT: The Law Offices of Vincent Wong Remind Rain Investors of a Lead Plaintiff Deadline of September 12, 2023
/PRNewswire/ -- Attention Rain Oncology Inc. ("Rain") (NASDAQ: RAIN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies Rain Oncology Inc.(RAIN) Investors of a Class Action Lawsuit and Upcoming Deadline
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN) of a class action securities lawsuit....
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rain Oncology Inc. - RAIN
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rain Oncology Inc. ("Rain" or the "Company") (NASDAQ: RAIN). Such investors are...
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Rain Oncology Inc. Investors with Losses to Secure Counsel Before Important September 12 Deadline in Securities Class Action - RAIN
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rain Oncology Inc. (NASDAQ: RAIN) between July 20,...